Predictors and pathways of in-hospital mortality in active vascular contrast extravasation detected on abdominopelvic CT.

OBJECTIVES: This study aimed to identify factors influencing in-hospital mortality in adult patients with active vascular contrast extravasation (AVCE) on abdominopelvic computed tomography (CT). METHODS: All consecutive patients with AVCE detected on CT between January 2019 and May 2022 were retrospectively included. Their data were compared through uni- and multivariable analyses between patients with and without in-hospital mortality. Path analysis was utilized to clarify the relationships among factors affecting mortality. RESULTS: There were 272 patients (60.2 ± 19.4 years, 150 men) included, of whom 70 experienced in-hospital mortality. Multivariable analysis revealed nonsurgery, chronic kidney disease (CKD) stage 4-5 or dialysis, prolonged partial thromboplastin time (PTT), minimum AVCE length > 8 mm, and a lower rate of packed red cell (PRC) transfusion were identified as independent predictors of in-hospital mortality (p = 0.005-0.048). Path analysis demonstrated direct influences of CKD4-5 or dialysis, prolonged PTT, and minimum AVCE length on mortality (coefficients 0.525-0.616; p = 0.009 to < 0.001). PRC transfusion impacted mortality through nonsurgery (coefficient 0.798, p = 0.003) and intensive care unit (ICU) admission (coefficients 0.025, p = 0.016), leading to subsequent death. Three AVCE spaces (free, loose, and tight) defined on CT were not directly associated with in-hospital mortality. CONCLUSION: In adults with AVCE on CT, AVCE size had a direct independent influence on mortality, highlighting the critical role of radiologists in detecting and characterizing this finding. Additionally, CKD4-5 or dialysis and prolonged PTT also directly influenced mortality, while the lower rate of PRC transfusion impacted mortality through nonsurgery and ICU admission. CLINICAL RELEVANCE STATEMENT: In patients with active vascular contrast extravasation (AVCE) on abdominopelvic CT, larger AVCE directly increased in-hospital mortality. Radiologists' detection and characterization of this finding is crucial, along with recognizing factors like CKD4-5, dialysis, and prolonged PTT to improve patient outcomes. KEY POINTS: Several factors independently predicted in-hospital mortality in patients with abdominopelvic AVCE. Extravasation length > 8 mm was the only imaging marker predictive of in-hospital mortality. Non-imaging factors correlated with in-hospital mortality, and PRC transfusion impacted mortality through nonsurgery and ICU admission pathways.

Sarcopenia as a Predictive Factor for Recurrence of Hepatocellular Carcinoma Following Radiofrequency Ablation.

BACKGROUND: Sarcopenia is a skeletal muscle mass deficiency and a potential prognostic factor for the recurrence of hepatocellular carcinoma (HCC). OBJECTIVE: To determine whether sarcopenia correlates with the recurrence rate of HCC after curative radiofrequency ablation (RFA) in early and very early HCC. METHODS: We retrospectively reviewed 669 HCC patients who underwent their first curative RFA at Siriraj hospital from 2011 to 2020. Fifty-six patients who were diagnosed with HCC by triple-phase CT scan and had complete response on follow-up CT were included. All patients underwent skeletal muscle index (SMI) assessment at level L3 vertebra and sarcopenia was defined by the cut-off values of 52.4 cm2/m2 for men and 38.5 cm2/m2 for women. We compared patients with and without sarcopenia. Time to recurrence was evaluated by the Kaplan-Meier method. Univariate and multivariate Cox regression analysis was performed. RESULTS: Sarcopenia was present in 37 of 56 patients (66.1%). There was no significant difference between groups except body mass index (BMI) (P<0.001) and serum alanine aminotransferase (ALT) (P=0.035). There was a promising result indicating the difference of time to recurrence between each group (P=0.046) and potential association of sarcopenia with HCC recurrence (HR=2.06; P=0.052). The Child-Pugh score and tumor number were independent risk factors for HCC recurrence (HR=2.04; P=0.005 and HR=2.68; P=0.017, respectively). CONCLUSION: Sarcopenia is a potential prognostic factor for recurrence of HCC in Thai patients who underwent RFA. A larger study is required to properly confirm this association.

The First Successful Transcatheter Closure of an Inferior Sinus Venosus Defect with Anomalous Drainage of the Right Lower Pulmonary Vein Using Bare and Covered Stents: A Single-Case Report.

Inferior sinus venosus defect (SVD) is less common than a superior one. The lower edge of the defect straddles the orifice of the inferior vena cava, and this makes surgical repair via bicaval cannulation a technical challenge. The orifice of the unroofed right pulmonary vein is caused by the interatrial communication in sinus venosus defects which results in partial anomalous pulmonary vein drainage (PAPVD). Novel transcatheter closure of a superior SVD has recently been described; however, transcatheter closure of an inferior SVD has not yet been reported in the published literature. Here, we report the first successful transcatheter closure of an inferior SVD with bare and covered stents and the rerouting of a PAPVD into the left atrium to avoid occlusion of the hepatic veins. In this single-case report, we carefully describe the planning process, how the procedure was performed, and the steps taken to recapture and reposition a migrated stent. Careful patient selection and intensive assessment of pulmonary and hepatic vein anatomy before and during the procedure were necessary to achieve a successful outcome.

Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA).

OBJECTIVE: To evaluate the biliary complication rates and efficacy of peribiliary tumor ablation using irreversible electroporation (IRE) or radiofrequency ablation (RFA). MATERIAL AND METHODS: This is a retrospective study of 42 consecutive patients with 44 peribiliary tumors (≤5 mm distance between the tumor margin and the primary or secondary bile duct). Data were collected between January 2014 and September 2020 from patients who underwent percutaneous liver ablation using IRE (n = 13) or RFA (n = 31). RESULTS: The median length of follow-up was 23.1 months. The mean tumor size was 17.2 ± 5.2 mm in IRE vs. 18.4 ± 7.0 mm in RFA (p= .56). Complete tumor ablation was achieved in 100% with a significantly larger ablation zone in the IRE group (3.8 ± 0.3 cm vs. 2.6 ± 0.6 cm, p<.001). Significant biliary complications occurred in one patient (7.7%) of the IRE group and in five patients (16.1%) of the RFA group. Significant risk factors for biliary complications included the RFA procedure (HR 9.71, p=.032) and proximity of the tumor to the bile duct (HR 0.63, p=.048). The local tumor progression (LTP) rates were 7.7% (IRE) vs. 21.5% (RFA) at 1 year, 23.1% (IRE) vs. 32.7% (RFA) at 2 years and 23.1% (IRE) vs. 44% (RFA) at 3 years, respectively (p=.289). CONCLUSIONS: The IRE and RFA procedures are safe and effective to treat peribiliary liver tumors. However, the RFA may have a higher risk of significant bile duct injury than IRE. The shorter distance between the bile duct and the tumor is a strong risk factor for biliary complications.

Prostatic Arterial Embolization for Control of Hematuria in Patients with Advanced Prostate Cancer.

Nine patients with advanced prostate cancer (stage T4) underwent prostatic arterial embolization (PAE) for refractory prostatic hematuria. Angiograms showed prostatic neovascularity in all cases, and complete PAE was achieved in 8 cases (89% technical success rate). Gross hematuria ceased after PAE in 6 cases, translating to a 67% clinical success rate. There were no PAE-related complications. At 3-month follow-up, 2 cases showed recurrent hematuria, 4 patients had died from PAE-unrelated etiologies, and only 3 patients survived and were without gross hematuria. PAE could represent an alternative option for patients with advanced prostate cancer to control hematuria.

The Outcome of Radiofrequency Ablation of Metastatic Liver Tumors.

OBJECTIVE: To determine outcome of radiofrequency ablation (RFA) in metastatic liver tumor and to evaluate related factors of residual or local tumor recurrences. MATERIAL AND METHOD: With Institutional Review Board approval, we retrospectively reviewed RFA procedure between June 2006 and September 2013. Fifty-seven metastatic nodules in 36 patients were treated. The primary tumors were colorectal carcinoma (n = 30), neuroendocrine tumor (n = 2), gallbladder carcinoma (n = 1), adenocarcinoma of head of pancreas (n = 1), and gastrointestinal stromal tumor (n = 2). Tumor characteristics, RFA techniques, success rate, complication, and follow-up imaging were reviewed and recorded Clinical outcome and overall survival were analyzed. RESULTS: Complete ablation were found in 48/57 nodules (84.2%). The mean follow-up time was 17.9 ± 13.1 months (range, 1 to 47 months). Local tumor recurrence were noted in 12/57 nodules (21.1%), which mean time to recurrence was 8.3 ± 3.8 months (2 to 15 months). Residual tumor was associate with tumor larger than 3 cm (p = 0.009). The 1-, 3-, and 5-year overall survival rates were 93.6%, 56.2%, and 20%, respectively. Median overall survival was 37.8 ± 10.9 months. Major complication rate occurred about 5.3%. CONCLUSION: Radiofrequency ablation is effective and feasible method to treat small metastatic liver tumor Tumor size larger than 3 cm is significant risk factor of residual tumor. Tumor in high-risk location is not associated either incomplete ablation or local tumor recurrence.

Preliminary Outcome of Microwave Ablation of Hepatocellular Carcinoma: Breaking the 3-cm Barrier?

PURPOSE: To evaluate preliminary outcomes after microwave ablation (MWA) of hepatocellular carcinoma (HCC) up to 5 cm and to determine the influence of tumor size. MATERIALS AND METHODS: Electronic records were searched for HCC and MWA. Between January 2011 and September 2014, 173 HCCs up to 5 cm were treated by MWA in 129 consecutive patients (89 men, 40 women; mean age, 66.9 y ± 9.5). Tumor characteristics related to local tumor progression and primary and secondary treatment efficacy were evaluated by univariate analysis. Outcomes were compared between tumors ≤ 3 cm and tumors > 3 cm. RESULTS: Technical success, primary efficacy, and secondary efficacy were 96.5%, 99.4%, and 94.2% at a mean follow-up period of 11.8 months ± 9.8 (range, 0.8-40.6 mo). Analysis of tumor characteristics showed no significant risk factor for local tumor progression, including subcapsular location (P = .176), tumor size (P = .402), and perivascular tumor location (P = .323). The 1-year and 2-year secondary or overall treatment efficacy rates for tumors measuring ≤ 3 cm were 91.2% and 82.1% and for tumors 3.1-5 cm were 92.3% and 83.9% (P = .773). The number of sessions to achieve secondary efficacy was higher in the larger tumor group (1.13 vs 1.06, P = .005). There were three major complications in 134 procedures (2.2%). CONCLUSIONS: With use of current-generation MWA devices, percutaneous ablation of HCCs up to 5 cm can be achieved with high efficacy.

Treatment of Anastomosis Stricture after Bilateral Ileal Ureter Reconstruction by Contralateral Retrograde Approach: Case Report.

A 37-year old woman with locally advanced uterine cervical cancer post concurrent chemoradiation, presented with an early anastomotic stricture after ileal ureter replacement due to the ischemic process during the reconstruction procedure. A bilateral ureteral stent was considered in order to relieve the obstructive uropathy. Multiple attempts were made to cannulate the stricture point between the right renal pelvis and ileal ureter, although all of them failed. The percutaneous contralateral nephrostomy tract was accessed and successfully used to perform retrograde approach cannulation. Balloon dilation at the stricture point and ureteral stent placement were successfully performed without any complications. Therefore, the contralateral retrograde approach for ureteral stent placement during bilateral ileal ureter reconstruction has been demonstrated to be both feasible and safe.

Incidence of complication and tumor recurrence after radiofrequency ablation in high-risk location of hepatocellular carcinoma patients.

OBJECTIVE: To evaluate complication, rate of residual, and tumor recurrence in high-risk location compared to non-high-risk location in hepatocellular carcinoma patients. MATERIAL AND METHOD: Radiofrequency ablation was performed on 409 tumors in Siriraj Hospital between October 2009 and May 2012. Eighty-eight nodules in 78 atients were treated by RF ablation, which divided into high risk and non-high-risk location. Complete ablation rate, residual tumor recurrent tumor, and complication were retrospectively reviewed. RESULTS: HCC nodules were in non-high-risk location 34 nodules (38.6%) and in high-risk location 54 nodules (61.4%). Complete tumor ablations were done in 34 nodules (100%) of non-high-risk location group and 50 nodules (92.6%) of high-risk location group. All residual tumors were four nodules (7.2%), which located in subcapsular location. Recurrent tumors were found in six nodules (6.8%), and mean time to recurrence were 210.2 days. Early complication was 10.2% and late complication was 4.5%. The recurrent tumor and complication were not significantly different between two groups. CONCLUSION: Radiofrequency ablation is effective treatment of hepatocellular carcinoma in high-risk location tumor There is no significant difference in complication and tumor recurrent rate between high-risk and non-high-risk group. However incidence of residual tumor is significantly increased in subcapsular location tumor

64-slice MDCT angiography of upper extremity in assessment of native hemodialysis access.

OBJECTIVE: To compare multidetector row computed tomographic (MDCT) angiography with conventional digital subtraction angiography (DSA) in the evaluation of vascular access stenoses in hemodialysis patients. MATERIALS AND METHODS: Twenty-one consecutive patients were imaged with MDCT angiography and subsequent DSA. The superficial vein of leg was used as the route for intravenous administration. The vascular stenosis was assessed in not significant (<50% stenosis), moderate stenosis (50%-74% stenosis), severe stenosis (75%-99%), and total occlusion (100%). The accuracy, sensitivity, specificity, positive, and negative predictive values were calculated for significant vascular stenosis using DSA as the standard reference. RESULTS: The sensitivity and specificity of MDCT angiography for the detection of significant hemodialysis vascular access were 100% (95% CI, 89.3%-100%) and 94.8% (95% CI, 89.1%-97.6%), respectively. The positive and negative predictive values were 84.2% (95% CI, 68.1%-93.4%) and 100% (95% CI, 95.8%-100%), respectively. The accuracy of MDCT angiography for detection of significant stenoses was 95.9% (95% CI, 91.4%-97.0%). CONCLUSIONS: MDCT angiography provides excellent correlation in vascular stenosis as compared with DSA in hemodialysis access. Complete assessment of entire vascular segments could be performing with MDCT angiography in planning before endovascular intervention or surgical correction.